. 2016 Oct 3;7(48):80033–80045. doi: 10.18632/oncotarget.12406

Table 2. The diagnostic value of combined Index in Training and Validation group.

	Group	Factor	AUC-ROC(95%CI)	Sensitivity	Specificity	Accuracy	PPV	NPV	+LR	-LR
PC VS non-PC	Training Group	CA19-9	0.895(0.838-0.952)	0.816	0.933	0.892	0.838	0.916	12.179	0.197
		Index1(miR-21,MIC-1,CA19-9)	0.968(0.947-0.989)^**	0.895	0.909	0.904	0.810	0.949	9.835	0.116
		Index2(miR-25,MIC-1,CA19-9)	0.967(0.945-0.989)^**	0.895	0.915	0.908	0.829	0.949	10.529	0.115
	Blinded validation Group	CA19-9	0.862(0.809-0.915)	0.720	0.859	0.818	0.678	0.881	5.106	0.326
		Index1(miR-21,MIC-1,CA199)	0.915(0.878-0.953)^*	0.878^*	0.874	0.875	0.742	0.945	6.968	0.140
		Index2(miR-25,MIC-1,CA199)	0.920(0.883-0.957)^*	0.841	0.919	0.896^*	0.812	0.933	10.383	0.173
PC VS HC	Training Group	CA19-9	0.914(0.861-0.968)	0.816	1.000	0.911	1.000	0.854	+	0.184
		Index1(miR-21,MIC-1,CA19-9)	0.990(0.981-1.000)^**	0.895	0.988	0.943	0.986	0.910	74.583	0.106
		Index2(miR-25,MIC-1,CA19-9)	0.984(0.970-0.998)^**	0.895	0.988	0.943	0.986	0.910	74.583	0.106
	Blinded validation Group	CA19-9	0.908(0.860-0.957)	0.720	0.955	0.841	0.937	0.785	16.000	0.293
		Index1(miR-21,MIC-1,CA19-9)	0.972(0.946-0.999)^**	0.878^*	0.989	0.935^*	0.986	0.897	79.818	0.123
		Index2(miR-25,MIC-1,CA19-9)	0.967(0.938-0.995)^**	0.841	1.000^*	0.924^*	1.000	0.871	+□	0.159
PC VS BPD ^a	Training Group	CA19-9	0.874(0.806-0.941)	0.816	0.773	0.806	0.925	0.548	3.595	0.238
		Index1(miR-21,MIC-1,CA19-9)	0.938(0.893-0.983)^*	0.895	0.818	0.878	0.944	0.692	4.918	0.128
		Index2(miR-25,MIC-1,CA19-9)	0.939(0.894-0.984)^*	0.895	0.818	0.878	0.944	0.692	4.918	0.128
	Blinded validation Group	CA19-9	0.821(0.749-0.894)	0.720	0.800	0.750	0.855	0.635	3.600	0.350
		Index1(miR-21,MIC-1,CA19-9)	0.889(0.831-0.947)^*	0.878^*	0.860	0.871^*	0.911	0.811	6.271	0.142
		Index2(miR-25,MIC-1,CA19-9)	0.865(0.799-0.930)	0.841	0.860	0.848^*	0.908	0.768	6.007	0.185
PC VS other gastrointestinal cancer	Training Group	CA19-9	0.876(0.813-0.939)	0.816	0.883	0.846	0.899	0.791	6.974	0.208
		Index1(miR-21,MIC-1,CA19-9)	0.948(0.914-0.981)^*	0.895	0.817	0.860	0.861	0.860	4.891	0.129
		Index2(miR-25,MIC-1,CA19-9)	0.954(0.923-0.985)^**	0.895	0.850	0.875	0.883	0.864	5.967	0.124
	Blinded validation Group	CA19-9	0.829(0.761-0.897)	0.720	0.767	0.739	0.808	0.667	3.090	0.365
		Index1(miR-21,MIC-1,CA19-9)	0.853(0.791-0.915)	0.878^*	0.717	0.810	0.809	0.811	3.102	0.170
		Index2(miR-25,MIC-1,CA19-9)	0.886(0.831-0.940)	0.841	0.850	0.845^*	0.885	0.797	5.607	0.187

BPD: Benign pancreatic disease. In the Training group only chronic pancreatitis patients were included. In the Blinded validation group patientswith both chronic pancreatitis and benign pancreatic tumor were included.

P <0.05 when compared with CA19-9;

^**

P<0.005 when compared.

Non-PC group included healthy controls, chronic pancreatitis, benign pancreatic tumor, colorectal cancer, gastric cancer and liver cancer; Abbreviation:PPV, Positive predictive value; NPV, Negative predictive value;+LR, Positive Likelihood Ratio; -LR, Negative Likelihood Ratio.